Sartorius Stedim Biotech

Sartorius Stedim Biotech is a provider of equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Co.'s solutions cover fermentation, filtration, purification, fluid management and lab technologies and membrane chromatography, including various conventional lab products to biopharmaceutical laboratories. Co.'s technologies, products and services are used to develop and manufacture medications and vaccines using biological methods. Co.'s products covers all upstream and downstream steps in the production of active pharmaceutical ingredients. It specializes in single-use products and offers technical consulting and services.
  • TickerDIM
  • ISINFR0013154002
  • ExchangeEuronext Paris
  • SectorHealth Care Equipment & Services
  • CountryFrance

SARTORIUS STEDIM BIOTECH sees a downgrade to Neutral on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of SARTORIUS STEDIM BIOTECH (FR), active in the Medical Supplies industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date June 5, 2020, the closing price was EUR 213.40 and its target price was estimated at EUR 177.76.

Expert Corporate Governance Service (ECGS)

Sartorius Stedim Biotech – AGM 24 June 2020

Changes published in the press release of 13/5/20 : - modification of the dividend from €0.64 to €0.35   ITEMS 6 AND 7: ECGS recommends to oppose the remuneration report and the "ex-post" remuneration of Joachim Kreuzburg which we deem excessive and which lacks transparency. ITEM 8: the same issues of transparency lead ECGS to also oppose the "ex-ante" remuneration policy. ITEM 4: Like last year, the Company did not make public many details on the Related-party Agreements report. This includes information on the ties between the Company and Sartorius AG (its largest shareholder) and this ...

Ahmed Ben Salem ...
  • Alain William
  • Alfred Glaser
  • Antoine Boivin-Champeaux
  • Baptiste Lebacq
  • Benoit Valleaux
  • Bruno Cavalier
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Emmanuel Matot
  • Geoffroy Michalet
  • Jean Sassus
  • Jerôme Bodin
  • Louis Boujard, CFA
  • Olfa Taamallah
  • Philippe Ourpatian
  • Pierre Tegner
  • Roland Pfaender,MBA,CFA,CCRA
  • Stephane Houri
  • Steven Gould
  • Sven Edelfelt
  • Virginie Rousseau
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 05/04/2020

...

Christophe-Raphaël Ganet

ODDO : Update

>Resilience confirmed: Q1 sales: +6% - To date, the sector has reported around 6% growth in Q1 revenues (Q2 will be more impacted: -10%e in our models). At the same time, we have lowered, on average, our projections by around 3% on 2020e revenues and by 9% on 2020e OIR.Finally, in the crisis, half of the issuers have, at this stage, cancelled the payment of their dividend.Performances: +14% (over the last 2 months) - At the same time, the sector'...

Dave Nicoski ...
  • Ross LaDuke

Int'l Macro Vision: Sector Synopsis

Int'l Equity Strategy Global equities were on a tear in early January, continuing the trend that began in 4Q2019. As global equities started to get extended, the coronavirus outbreak hit in mid-January, leading to some market setbacks and deterioration in market indicators as global growth expectations were dialed-in. Despite this deterioration, what was important to us was that there were not any breakdowns. Even the areas of the market most-directly affected by the outbreak -- China (MSCI China) and EM (MSCI EM) -- were not breaking down. To us, this was a reassuring sign of underlying stre...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

EM Pullback Opportunity Supporting our global bull market thesis, uptrends remain intact for the major global indexes (MSCI ACWI, ACWI ex-US, EAFE, and EM). At this point, concerns surrounding the Wuhan coronavirus have led to some market setbacks and deterioration in market indicators, however they have not resulted in breakdowns. This is true even for areas of the market most-directly affected, including China (MSCI China) and emerging markets (MSCI EM). For these reasons and, as long as there is no significant additional damage, we view recent weakness as a buying opportunity - especially ...

Dave Nicoski ...
  • Ross LaDuke

Int'l Macro Vision: Sector Synopsis

Int'l Equity Strategy In using technical analysis, we let the market be our guide. That is, we analyze what is true in the market, utilizing the vast array of tools in our technical analysis toolbox which we then formulate into our outlook using a weight of the evidence approach. In a world where there are no shortages of things to worry about (trade wars, central banks, Trump impeachment, negative interest rates, low global growth, Brexit, Manufacturing weakness, elections, Hong Kong protests, the list goes on...), our tools help us cut through the noise and conjecture. After all, what if th...

Dave Nicoski ...
  • Ross LaDuke

Int'l Macro Vision: Global Equity Strategy

Int'l Equity Strategy Global equities staged an impressive rally over the first four months of 2019. The nearly unabated advance allowed the broad major indexes (MSCI ACWI, ACWI ex-US, and EAFE) to break topside critical 14-month downtrends which began in January 2018. Heading into May, YTD uptrends were ubiquitous and market participants were generally of the belief that a US-China trade deal was a foregone conclusion. Then came Trump's May 5th tweets claiming China was attempting to renegotiate, and that tariffs would increase from 10% to 25%. The tariff escalation contributed to uptrend br...

Jérôme VINERIER

Short term view - SARTORIUS STEDIM BIOTECH : The background trend is clearly bullish.

The background trend is clearly bullish. The recent fall is a consolidation that may be interrupted as it approaches de €97.70. The next target is at €120.50. The trend would be invalidated below the support at €80.80.

Christophe-Raphaël Ganet

ODDO : Update

>Resilience confirmed: Q1 sales: +6% - To date, the sector has reported around 6% growth in Q1 revenues (Q2 will be more impacted: -10%e in our models). At the same time, we have lowered, on average, our projections by around 3% on 2020e revenues and by 9% on 2020e OIR.Finally, in the crisis, half of the issuers have, at this stage, cancelled the payment of their dividend.Performances: +14% (over the last 2 months) - At the same time, the sector'...

Christophe-Raphaël Ganet

ODDO : Update Santé

>Résilience plutôt confortée: CA T1: +6% - A ce jour, le secteur a publié une croissance d’environ 6% des CA T1 (T2 sera plus impacté : -10%e dans nos modèles). Dans le même temps, nous avons abaissé, en moyenne, nos projections d’environ 3% sur le CA 2020e, et de 9%, au niveau du ROC 2020e.Enfin, dans la crise, la moitié des émetteurs ont, à ce stade, annulé le versement de leur dividende.Performance boursière: +14% (sur les 2 derniers mois) - P...

Christophe-Raphaël Ganet

Sartorius Stedim Biotech : Q1 2020 sales/EBITDA beat our expectations, guidance raised, target price lifted to € 202

>Q1 2020: robust sales, backlog and margin - SSB reported € 422.1m in Q1 sales (+23.1% and +22.3% cc) with € 126.7m in EBITDA (+29%). The group appears to have turned in strong growth across regions and segments. Total sales break down as follows: € 167.6m for EMEA (+19.2% and +19% cc), €152.7m for North America (+22.4% and +23% cc), and Asia-Pacific €101.7m (+31% and +32% cc). They include Biological Industries (cell culture media), acquired in December 2019.Ord...

Christophe-Raphaël Ganet

Sartorius Stedim Biotech : CA / EBITDA T1 2020 supérieur à notre attente – Guidances relevées – OC relevé à 202 €

>T1 2020 : CA, backlog et marge très solides - SSB publie un CA T1 à 422.1 M€ (+23.1% et +22.3% à tcc.) et un EBITDA qui ressort à 126.7 M€ (+29%). Toutes les zones et segments semblent en croissance soutenue. Le CA se répartit comme suit : 167.6 M€ pour l’EMEA (+19.2% et +19% à tcc.), 152.7 M€ sur l’Amérique du Nord (+22.4% et +23% à tcc.), et Asie-Pacifique, 101.7 M€ (+31% et +32% à tcc.). Il inclut Biological Industries (milieux de culture cellulaire), acquis en dé...

Christophe-Raphaël Ganet

ODDO : Q1 2020 previews

>Recent contact with companies in the sector - Here we outline our main takeaways from our recent contact with a number of companies (Boiron, Bastide, bioMérieux and Ipsen).Generally, the tone was not one of doom and gloom, and the resilience in sales is being confirmed (the defensive qualities of the healthcare sector are coming through fully).Q1 previews (+5% estimated) - In this update, we are giving our previews for the stocks in our coverage...

Ahmed Ben Salem ...
  • Alain William
  • Alfred Glaser
  • Antoine Boivin-Champeaux
  • Baptiste Lebacq
  • Benoit Valleaux
  • Bruno Cavalier
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Emmanuel Matot
  • Geoffroy Michalet
  • Jean Sassus
  • Jerôme Bodin
  • Louis Boujard, CFA
  • Olfa Taamallah
  • Philippe Ourpatian
  • Pierre Tegner
  • Roland Pfaender,MBA,CFA,CCRA
  • Stephane Houri
  • Steven Gould
  • Sven Edelfelt
  • Virginie Rousseau
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 05/04/2020

...

Alain William ...
  • Aurelien Sivignon
  • Baptiste Lebacq
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Nicolas David
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 04/05/2020 Date Performance depuis l’entrée Date Performance depuis l’entrée

...

Ahmed Ben Salem ...
  • Alain William
  • Alfred Glaser
  • Antoine Boivin-Champeaux
  • Baptiste Lebacq
  • Benoit Valleaux
  • Bruno Cavalier
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Emmanuel Matot
  • Geoffroy Michalet
  • Jean Sassus
  • Jerôme Bodin
  • Louis Boujard, CFA
  • Olfa Taamallah
  • Philippe Ourpatian
  • Pierre Tegner
  • Roland Pfaender,MBA,CFA,CCRA
  • Stephane Houri
  • Steven Gould
  • Sven Edelfelt
  • Virginie Rousseau
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 04/05/2020

...

Alain William ...
  • Alfred Glaser
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Fatma Agnès Hamdani
  • Jerôme Bodin
  • Johanna Jourdain
  • Matthias Desmarais
  • Michael Foundoukidis
  • Pierre Tegner
  • Samantha Jeary
  • Stephane Houri

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 04/21/2020

Three fundamental conclusions can be drawn from our research, which has been conducted on a model recast with a view to capturing the latest governance trends: (i) Eurazeo and Plastic Omnium have the best scores based on our analysis model, with a very clear lead for Eurazeo; (ii) France is trying (possibly too hard) to protect itself against activist funds; and (iii) the Covid-19 crisis is threatening the organisation of AGMs and calling into question the principle of shareholder val...

SARTORIUS STEDIM BIOTECH sees a downgrade to Neutral on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of SARTORIUS STEDIM BIOTECH (FR), active in the Medical Supplies industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date June 5, 2020, the closing price was EUR 213.40 and its target price was estimated at EUR 177.76.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Expert Corporate Governance Service (ECGS)

Sartorius Stedim Biotech – AGM 24 June 2020

Changes published in the press release of 13/5/20 : - modification of the dividend from €0.64 to €0.35   ITEMS 6 AND 7: ECGS recommends to oppose the remuneration report and the "ex-post" remuneration of Joachim Kreuzburg which we deem excessive and which lacks transparency. ITEM 8: the same issues of transparency lead ECGS to also oppose the "ex-ante" remuneration policy. ITEM 4: Like last year, the Company did not make public many details on the Related-party Agreements report. This includes information on the ties between the Company and Sartorius AG (its largest shareholder) and this ...

Expert Corporate Governance Service (ECGS)

Sartorius Stedim Biotech, March 26 2019

Item 9: This year, the re-election of Joachim Kreuzburg, CEO, as director is up for vote. ECGS recommends opposing this item due to the lack of counter-power and the absence of information regarding performance and environmental issues. Item 4: Much like last year, the Company did not make public many details on the Related- party Agreements report. This includes information on the tie between the Company and Sartorius AG (their main shareholder) and the lack of transparency is a serious breach against other shareholders rights.

Florian Béchaz

Sartorius Stedim Biotech, 26 Mars 2019

Proxinvest attire l'attention des actionnaires sur différents points lors de cette assemblée générale. Tout d'abord le renouvellement de Joachim Kreuzburg. Ce dernier est le Président Directeur Général de la société. Proxinvest a donc analysé la présence de contre-pouvoirs, la performance économique et la performance environnementale. Bien que la performance boursière soit à saluer, les autres éléments ne permettent pas une recommandation positive. Ensuite, comme l'année précédente, le fait que seulement une partie des transactions liant la société et Sartorius AG, son premier actionnaire, s...

Sartorius Stedim Biotech - Assemblée générale des actionnaires du 26 mars 2019

Proxinvest publiera une étude analysant les résolutions proposées lors de la tenue de l’assemblée générale des actionnaires. Vous pouvez l'acquérir dès à présent et elle vous sera adressée par ResearchPool une fois publiée.

Sartorius Stedim Biotech - Assemblée générale des actionnaires du 26 mars 2019

Proxinvest publiera une étude analysant les résolutions proposées lors de la tenue de l’assemblée générale des actionnaires. Vous pouvez l'acquérir dès à présent et elle vous sera adressée par ResearchPool une fois publiée.

Dominic Rose ...
  • Naresh Chouhan

Global CDMOs - Impact of Alzheimer's Windfall

Our unique coverage of the biggest CDMO’s allows us to quantify the financial impact on the industry of a potential Alzheimer’s windfall from Biogen’s aducanumab. As the FDA filing draws closer, Biogen are likely to be involved in intense negotiations to find alternative sources of supply. Our highly detailed analysis shows how much aducanumab will need to be produced, who the winners are likely to be, the revenue uplift they may enjoy and the NPV uplift to each player. Lonza & Samsung Biologics are likely the biggest winners with Catalent close behind.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch